Hedgehog signaling is a potent regulator of liver lipid metabolism and reveals a GLI-code associated with steatosis

eLife

Volumn 5, Issue MAY2016, 2016, Pages

  Matz Soja, Madlen ^a   Rennert, Christiane ^a   Schönefeld, Kristin ^a   Aleithe, Susanne ^a   Boettger, Jan ^a   Schmidt Heck, Wolfgang ^b   Weiss, Thomass ^c   Hovhannisyan, Amalya ^a,d   Zellmer, Sebastian ^a   Klöting, Nora ^a   Schulz, Angela ^a   Kratzsch, Jürgen ^a   Guthke, Reinhardt ^b   Gebhardt, Rolf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d Westpfalz Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CRE RECOMBINASE; CYCLOPAMINE; GLUCOSE; GLYCOGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN; INSULIN RECEPTOR; LANOSTEROL; LOW DENSITY LIPOPROTEIN; PROTEIN PATCHED 1; PROTEIN PATCHED 2; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; GLI1 PROTEIN, HUMAN; GLI3 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; NERVE PROTEIN; SMO PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; CELL VIABILITY ASSAY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEATOSIS; ANIMAL; DEFICIENCY; GENE EXPRESSION PROFILING; LIVER; METABOLISM; MICROARRAY ANALYSIS; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIPID METABOLISM; LIVER; MICE; MICE, TRANSGENIC; MICROARRAY ANALYSIS; NERVE TISSUE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION; SMOOTHENED RECEPTOR; ZINC FINGER PROTEIN GLI1;

EID: 84971667597     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.13308     Document Type: Article

References (73)

1. Ables GP. 2012. Update on pparg and nonalcoholic fatty liver disease. PPAR Research 2012. 912351. doi: 10.1155/2012/912351.
2. Ahmed A, Wong RJ, Harrison SA. 2015. Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes. Clinical Gastroenterology and Hepatology 13:2062–2070. doi: 10.1016/j.cgh.2015.07.029.
3. Alderete TL, Byrd-Williams CE, Toledo-Corral CM, Conti DV, Weigensberg MJ, Goran MI. 2011. Relationships between IGF-1 and IGFBP-1 and adiposity in obese african-american and latino adolescents. Obesity 19:933–938. doi: 10.1038/oby.2010.211.
4. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Sato R, Kimura S, Ishibashi S, Yamada N. 2002. Transcriptional activities of nuclear srebp-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. Journal of Lipid Research 43:1220–1235.
5. Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S. 2006. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Developmental Cell 10:759–770. doi: 10.1016/j.devcel.2006.03.015.
6. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z, Galon J. 2009. Cluego: A cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25:1091–1093. doi: 10.1093/bioinformatics/btp101.
7. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248–254. doi: 10.1016/0003-2697(76)90527-3.
8. Böttger J, Arnold K, Thiel C, Rennert C, Aleithe S, Hofmann U, Vlaic S, Sales S, Shevchenko A, Matz-Soja M. 2015. Rnai in murine hepatocytes: The agony of choice–a study of the influence of lipid-based transfection reagents on hepatocyte metabolism. Archives of Toxicology 89:1579–1588. doi: 10.1007/s00204-015-1571-0.
9. Chafey P, Finzi L, Boisgard R, Caüzac M, Clary G, Broussard C, Pégorier JP, Guillonneau F, Mayeux P, Camoin L, Tavitian B, Colnot S, Perret C. 2009. Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the wnt pathway. Proteomics 9:3889–3900. doi: 10.1002/pmic.200800609.
10. Chow JD, Lawrence RT, Healy ME, Dominy JE, Liao JA, Breen DS, Byrne FL, Kenwood BM, Lackner C, Okutsu S, Mas VR, Caldwell SH, Tomsig JL, Cooney GJ, Puigserver PB, Turner N, James DE, Villén J, Hoehn KL. 2014. Genetic inhibition of hepatic acetyl-coa carboxylase activity increases liver fat and alters global protein acetylation. Molecular Metabolism 3:419–431. doi: 10.1016/j.molmet.2014.02.004.
11. Claus C, Schönefeld K, Hübner D, Chey S, Reibetanz U, Liebert UG. 2013. Activity increase in respiratory chain complexes by rubella virus with marginal induction of oxidative stress. Journal of Virology 87:8481–8492. doi: 10.1128/JVI.00533-13.
12. Daily K, Patel VR, Rigor P, Xie X, Baldi P. 2011. Motifmap: Integrative genome-wide maps of regulatory motif sites for model species. BMC Bioinformatics 12:495. doi: 10.1186/1471-2105-12-495.
13. Damiano F, Gnoni GV, Siculella L. 2009. Functional analysis of rat liver citrate carrier promoter: Differential responsiveness to polyunsaturated fatty acids. The Biochemical Journal 417:561–571. doi: 10.1042/BJ20081082.
14. Dentin R, Pégorier JP, Benhamed F, Foufelle F, Ferre´ P, Fauveau V, Magnuson MA, Girard J, Postic C. 2004. Hepatic glucokinase is required for the synergistic action of chrebp and srebp-1c on glycolytic and lipogenic gene expression. The Journal of Biological Chemistry 279:20314–20326. doi: 10.1074/jbc.M312475200.
15. Dongiovanni P, Romeo S, Valenti L. 2015. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. BioMed Research International 2015. 2015:460190. doi: 10.1155/2015/460190.
16. Duez H, Staels B. 2008. Rev-erb alpha gives a time cue to metabolism. FEBS Letters 582:19–25. doi: 10.1016/j.febslet.2007.08.032.
17. Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. 2015. Liver fibrosis markers of nonalcoholic steatohepatitis. World Journal of Gastroenterology 21:7427–7435. doi: 10.3748/wjg.v21.i24.7427.
18. Fabbrini E, Sullivan S, Klein S. 2010. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51:679–689. doi: 10.1002/hep.23280.
19. Fernández-Zapico ME. 2008. Primers on molecular pathways GLI: More than just hedgehog? Pancreatology 8: 227–229. doi: 10.1159/000134271.
20. Fon Tacer K, Rozman D. 2011. Nonalcoholic fatty liver disease: Focus on lipoprotein and lipid deregulation. Journal of Lipids 2011. 2011:783976. doi: 10.1155/2011/783976.
21. Gebhardt R. 1992. Metabolic zonation of the liver: Regulation and implications for liver function. Pharmacology & Therapeutics 53:275–354. doi: 10.1016/0163-7258(92)90055-5.
22. Gebhardt R, Hovhannisyan A. 2010. Organ patterning in the adult stage: The role of wnt/beta-catenin signaling in liver zonation and beyond. Developmental Dynamics 239:45–55. doi: 10.1002/dvdy.22041.
23. Gebhardt R, Lerche KS, Götschel F, Günther R, Kolander J, Teich L, Zellmer S, Hofmann HJ, Eger K, Hecht A, Gaunitz F. 2010. 4-aminoethylamino-emodin–a novel potent inhibitor of gsk-3beta–acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin. Journal of Cellular and Molecular Medicine 14:1276– 1293. doi: 10.1111/j.1582-4934.2009.00701.x
24. Gebhardt R, Matz-Soja M. 2014. Liver zonation: Novel aspects of its regulation and its impact on homeostasis. World Journal of Gastroenterology 20:8491–8504. doi: 10.3748/wjg.v20.i26.8491.
25. Gómez-Lechón MJ, Ponsoda X, Castell JV. 1996. A microassay for measuring glycogen in 96-well-cultured cells. Analytical Biochemistry 236:296–301. doi: 10.1006/abio.1996.0170.
26. Gu D, Xie J. 2015. Non-canonical hh signaling in cancer-current understanding and future directions. Cancers 7: 1684–1698. doi: 10.3390/cancers7030857.
27. Gurdziel K, Vogt KR, Schneider G, Richards N, Gumucio DL. 2016. Computational prediction and experimental validation of novel hedgehog-responsive enhancers linked to genes of the hedgehog pathway. BMC Developmental Biology 16. doi: 10.1186/s12861-016-0106-0.
28. Hovhannisyan A, Matz M, Gebhardt R. 2009. From teratogens to potential therapeutics: Natural inhibitors of the hedgehog signaling network come of age. Planta Medica 75:1371–1380. doi: 10.1055/s-0029-1185979.
29. Hui ST, Parks BW, Org E, Norheim F, Che N, Pan C, Castellani LW, Charugundla S, Dirks DL, Psychogios N, Neuhaus I, Gerszten RE, Kirchgessner T, Gargalovic PS, Lusis AJ. 2015. The genetic architecture of NAFLD among inbred strains of mice. eLife 4:e05607. doi: 10.7554/eLife.05607.
30. Infante P, Alfonsi R, Botta B, Mori M, Di Marcotullio L. 2015. Targeting GLI factors to inhibit the hedgehog pathway. Trends in Pharmacological Sciences 36:547–558. doi: 10.1016/j.tips.2015.05.006.
31. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y, Okumura T. 2005. Increased expression of ppargamma in high fat diet-induced liver steatosis in mice. Biochemical and Biophysical Research Communications 336:215–222. doi: 10.1016/j.bbrc.2005.08.070.
32. Itoh M, Suganami T, Nakagawa N, Tanaka M, Yamamoto Y, Kamei Y, Terai S, Sakaida I, Ogawa Y. 2011. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. The American Journal of Pathology 179:2454–2463. doi: 10.1016/j.ajpath.2011.07.014.
33. Jakobsson A, Jörgensen JA, Jacobsson A. 2005. Differential regulation of fatty acid elongation enzymes in brown adipocytes implies a unique role for elovl3 during increased fatty acid oxidation. American Journal of Physiology. Endocrinology and Metabolism 289:E517–E526. doi: 10.1152/ajpendo.00045.2005.
34. Jung Y, Witek RP, Syn WK, Choi SS, Omenetti A, Premont R, Guy CD, Diehl AM. 2010. Signals from dying hepatocytes trigger growth of liver progenitors. Gut 59:655–665. doi: 10.1136/gut.2009.204354.
35. Klingmüller U, Bauer A, Bohl S, Nickel PJ, Breitkopf K, Dooley S, Zellmer S, Kern C, Merfort I, Sparna T, Donauer J, Walz G, Geyer M, Kreutz C, Hermes M, Götschel F, Hecht A, Walter D, Egger L, Neubert K, et al. 2006. Primary mouse hepatocytes for systems biology approaches: A standardized in vitro system for modelling of signal transduction pathways. Systems Biology 153:433–447. doi: 10.1049/ip-syb:20050067.
36. Liu Q. 2012. Evaluation of fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. Molecular Medicine Reports. doi: 10.3892/mmr.2012.953.
37. Law KKL, Makino S, Mo R, Zhang X, Puviindran V, Hui Chi-chung. 2012. Antagonistic and cooperative actions of Kif7 and Sufu define graded intracellular Gli activities in Hedgehog signaling. PloS One 7:e50193. doi: 10.1371/journal.pone.0050193.
38. Long F, Zhang XM, Karp S, Yang Y, McMahon AP. 2001. Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. Development 128: 5099–5108.
39. Mallea-Gil MS, Ballarino MC, Spiraquis A, Iriarte M, Kura M, Gimenez S, Oneto A, Guitelman M, Machado R, Miguel CM. 2012. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterologica Latinoamericana 42:20–26.
40. Matz-Soja M, Aleithe S, Marbach E, Böttger J, Arnold K, Schmidt-Heck W, Kratzsch J, Gebhardt R. 2014. Hepatic hedgehog signaling contributes to the regulation of IGF1 and IGFBP1 serum levels. Cell Communication and Signaling 12:11. doi: 10.1186/1478-811X-12-11.
41. Monga SP. 2015. b-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 148:1294–1310. doi: 10.1053/j.gastro.2015.02.056.
42. Morishita S, Mochizuki K, Goda T. 2014. Bindings of chrebp and SREBP1, and histone acetylation around the rat liver fatty acid synthase gene are associated with induction of the gene during the suckling-weaning transition. Journal of Nutritional Science and Vitaminology 60:94–100. doi: 10.3177/jnsv.60.94.
43. Nagase T, Yamakawa H, Tadokoro S, Nakajima D, Inoue S, Yamaguchi K, Itokawa Y, Kikuno RF, Koga H, Ohara O. 2008. Exploration of human orfeome: High-throughput preparation of ORF clones and efficient characterization of their protein products. DNA Research 15:137–149. doi: 10.1093/dnares/dsn004.
44. Nunnari JJ, Zand T, Joris I, Majno G. 1989. Quantitation of oil red O staining of the aorta in hypercholesterolemic rats. Experimental and Molecular Pathology 51:1–8. doi: 10.1016/0014-4800(89)90002-6.
45. Omenetti A, Choi S, Michelotti G, Diehl AM. 2011. Hedgehog signaling in the liver. Journal of Hepatology 54: 366–373. doi: 10.1016/j.jhep.2010.10.003.
46. Patankar JV, Obrowsky S, Doddapattar P, Hoefler G, Battle M, Levak-Frank S, Kratky D. 2012. Intestinal GATA4 deficiency protects from diet-induced hepatic steatosis. Journal of Hepatology 57:1061–1068. doi: 10.1016/j.jhep.2012.06.028.
47. Petrosillo G, Portincasa P, Grattagliano I, Casanova G, Matera M, Ruggiero FM, Ferri D, Paradies G. 2007. Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin. Biochimica Et Biophysica Acta 1767:1260–1267. doi: 10.1016/j.bbabio.2007.07.011.
48. Postic C, Girard J. 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. The Journal of Clinical Investigation 118:829–838. doi: 10.1172/JCI34275.
49. Probst I, Schwartz P, Jungermann K. 1982. Induction in primary culture of ’gluconeogenic’ and ’glycolytic’ hepatocytes resembling periportal and perivenous cells. European Journal of Biochemistry / FEBS 126:271–278. doi: 10.1111/j.1432-1033.1982.tb06775.x
50. Ramanathan C, Xu H, Khan SK, Shen Y, Gitis PJ, Welsh DK, Hogenesch JB, Liu AC. 2014. Cell type-specific functions of period genes revealed by novel adipocyte and hepatocyte circadian clock models. PLoS Genetics 10:e1004244. doi: 10.1371/journal.pgen.1004244.
51. Reed BD, Charos AE, Szekely AM, Weissman SM, Snyder M. 2008. Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes. PLoS Genetics 4:e1000133. doi: 10.1371/journal.pgen.1000133.
52. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics 40:1461–1465. doi: 10.1038/ng.257.
53. Ruiz i Altaba A. 1999. Gli proteins and hedgehog signaling: Development and cancer. Trends in Genetics 15: 418–425. doi: 10.1016/S0168-9525(99)01840-5.
54. Ruiz i Altaba A, Nguyên V, Palma V. 2003. The emergent design of the neural tube: Prepattern, SHH morphogen and GLI code. Current Opinion in Genetics & Development 13:513–521. doi: 10.1016/j.gde.2003.08.005.
55. Ruiz i Altaba A, Mas C, Stecca B. 2007. The gli code: An information nexus regulating cell fate, stemness and cancer. Trends in Cell Biology 17:438–447. doi: 10.1016/j.tcb.2007.06.007.
56. Sandrock M, Schulz A, Merkwitz C, Schöneberg T, Spanel-Borowski K, Ricken A. 2009. Reduction in corpora lutea number in obese melanocortin-4-receptor-deficient mice. Reproductive Biology and Endocrinology 7:24. doi: 10.1186/1477-7827-7-24.
57. Schleicher J, Tokarski C, Marbach E, Matz-Soja M, Zellmer S, Gebhardt R, Schuster S. 2015. Zonation of hepatic fatty acid metabolism - The diversity of its regulation and the benefit of modeling. Biochimica Et Biophysica Acta 1851:641–656. doi: 10.1016/j.bbalip.2015.02.004.
58. Schmidt-Heck W, Matz-Soja M, Aleithe S, Marbach E, Guthke R, Gebhardt R. 2015. Fuzzy modeling reveals a dynamic self-sustaining network of the GLI transcription factors controlling important metabolic regulators in adult mouse hepatocytes. Molecular bioSystems 11:2190–2197. doi: 10.1039/c5mb00129c
59. Schönig K, Schwenk F, Rajewsky K, Bujard H. 2002. Stringent doxycycline dependent control of CRE recombinase in vivo. Nucleic Acids Research 30:e134. doi: 10.1093/nar/gnf134.
60. Sicklick JK, Li Y, Melhem A, Schmelzer E, Zdanowicz M, Huang J, Caballero M, Fair JH, Ludlow JW, McClelland RE. 2006. Hedgehog signaling maintains resident hepatic progenitors throughout life. AJP: Gastrointestinal and Liver Physiology 290:G859–G870. doi: 10.1152/ajpgi.00456.2005.
61. Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, Cohen JC, Hobbs HH. 2015. Pnpla3i148m knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61:108–118. doi: 10.1002/hep.27242.
62. Stecca B, Ruiz I Altaba A. 2010. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-hedgehog signals. Journal of Molecular Cell Biology 2:84–95. doi: 10.1093/jmcb/mjp052.
63. Suh JM, Gao X, McKay J, McKay R, Salo Z, Graff JM. 2006. Hedgehog signaling plays a conserved role in inhibiting fat formation. Cell Metabolism 3:25–34. doi: 10.1016/j.cmet.2005.11.012.
64. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. 2015. String v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Research 43:D447–D452. doi: 10.1093/nar/gku1003.
65. Teperino R, Aberger F, Esterbauer H, Riobo N, Pospisilik JA. 2014. Canonical and non-canonical hedgehog signalling and the control of metabolism. Seminars in Cell & Developmental Biology 33:81–92. doi: 10.1016/j.semcdb.2014.05.007.
66. Toku AE, Tekir SD, Özbayraktar FB, Ülgen KÖ. 2011. Reconstruction and crosstalk of protein-protein interaction networks of wnt and hedgehog signaling in drosophila melanogaster. Computational Biology and Chemistry 35:282–292. doi: 10.1016/j.compbiolchem.2011.07.002.
67. Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B. 2011. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. International Journal of Experimental Pathology 92:413–421. doi: 10.1111/j.1365-2613.2011.00793.x
68. Völzke H, Nauck M, Rettig R, Dörr M, Higham C, Brabant G, Wallaschofski H. 2009. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. European Journal of Endocrinology / European Federation of Endocrine Societies 161:705–713. doi: 10.1530/EJE-09-0374.
69. Wei Y, Rector RS, Thyfault JP, Ibdah JA. 2008. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World Journal of Gastroenterology 14:193. doi: 10.3748/wjg.14.193.
70. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. 2004. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432:1027–1032. doi: 10.1038/nature03047.
71. Woo CW, Siow YL, Pierce GN, Choy PC, Minuk GY, Mymin D, O K. 2005. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. American Journal of Physiology. Endocrinology and Metabolism 288:E1002–E1010. doi: 10.1152/ajpendo.00518.2004.
72. Zellmer S, Sickinger S, Schmidt-Heck W, Guthke R, Gebhardt R. 2009. Heterogeneous expression of suppressor of cytokine signalling 2 (SOCS-2) in liver tissue. Journal of Anatomy 215:176–183. doi: 10.1111/j.1469-7580.2009.01085.x
73. Zhang QQ, Lu LG. 2015. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. Journal of Clinical and Translational Hepatology 3:78–84. doi: 10.14218/JCTH.2014.00037